시장보고서

상품코드

1781986

희귀질환 치료 시장 : 치료 영역별, 약제 유형별, 투여 형태별, 유통 채널별, 환자 연령층별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Rare Disease Treatment Market, By Therapeutic Area, By Drug Type, By Mode of Administration, By Distribution Channel, By Patient Age Group, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 07월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 322 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

희귀질환 치료 시장 규모는 2024년에 2,162억 5,049만 달러에 달하며, 2025-2032년에 CAGR 11.90%로 확대

희귀질환 치료제 시장 - 시장 역학

유전자 연구의 발전으로 희귀질환 치료법 개발 가속화

유전자 연구의 발전은 희귀질환 치료에 큰 영향을 미치고 있으며, 표적치료와 맞춤형 의료를 가능하게 하고 있습니다. 미국 국립보건원(NIH)에 따르면 희귀질환의 80%가 유전으로 인한 것으로 나타나 진단과 치료에 있으며, 유전체학의 중요성이 강조되고 있습니다. 미국 식품의약국(FDA)은 수많은 유전자 치료제에 희귀질환 치료제(희귀의약품) 지위를 부여하여 신속한 승인과 기술 혁신을 촉진하고 있습니다. 또한 국제희귀질환연구컨소시엄(IRDiRC)과 같은 세계 구상은 진단 및 치료법 개발을 가속화하기 위해 국가와 부문을 초월한 협력을 촉진하고 있습니다. 이러한 노력은 환자 등록 및 유전자 검사 프로그램 증가와 함께 조기 발견과 맞춤형 치료를 강화하여 궁극적으로 전 세계 수백만 명의 희귀질환 환자들의 삶의 질을 향상시키고 있습니다.

희귀질환 치료제 시장 - 주요 인사이트

당사의 리서치 애널리스트들의 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 동안 연평균 약 11.90%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

치료 영역별로는 혈액학이 2024년 가장 높은 시장 점유율을 보였습니다.

약제 유형별로는 생물제제가 2024년 주요 약제 유형입니다.

투여 형태별로는 주사가 2024년 주요 투여 형태였습니다.

유통 채널별로는 2024년 유통 채널은 전문약국이 주도하고 있습니다.

환자 연령대별로는 2024년 성인이 주요 환자 연령층이 될 것임.

지역별로는 북미가 2024년 매출 1위를 기록했습니다.

희귀질환 치료제 시장 - 세분화 분석

세계 희귀질환 치료제 시장은 치료 영역, 약물 유형, 투여 형태, 유통 채널, 환자 연령대, 지역에 따라 세분화됩니다.

시장은 치료 영역에 따라 혈액학, 신경학, 종양학, 대사질환, 면역학, 감염질환, 내분비질환, 심혈관질환, 근골격계질환 등 9가지 카테고리로 나뉩니다. 혈액 내과는 표적치료제를 이용한 혈액질환에 중점을 두고 있습니다. 신경과에서는 첨단 치료법을 통해 희귀 신경질환을 치료합니다. 종양학은 특수한 암 치료법을 개발합니다. 대사성 질환은 효소 보충에 의존합니다. 면역학은 면역 결핍을 대상으로 하고, 감염학은 희귀 감염을 대상으로 합니다. 내분비 질환, 심혈관 질환, 근골격계 질환에는 새로운 표적치료제가 등장하고 있습니다.

시장은 약물 유형에 따라 생물제제와 비생물제제의 두 가지 범주로 나뉩니다. 생물제제는 항체나 유전자 치료와 같은 복잡한 분자로 희귀질환 치료를 지배하고 표적 작용을 기재하고 있습니다. 비생물제제에는 보다 전통적인 치료 옵션을 제공하는 저분자 약물이 포함되며, 다양한 희귀질환의 증상 관리 및 지지요법에 사용되는 경우가 많습니다.

희귀질환 치료제 시장 - 지역적 인사이트

희귀질환 치료제 시장은 헬스케어 인프라, 규제 정책, 인식 수준에 영향을 받아 지역적 변동성이 큰 것으로 나타났습니다. 북미는 첨단화된 의료 시스템, 강력한 정부 지원, 국립보건원(NIH)과 같은 기관의 희귀질환 연구에 대한 풍부한 자금 지원으로 인해 여전히 유력한 지역으로 남아 있습니다. 유럽은 종합적인 희귀질환 네트워크, 더 나은 진단과 치료를 위한 국가 간 협력을 촉진하는 유럽 레퍼런스 네트워크(ERNs)와 같은 구상을 통해 그 뒤를 잇고 있습니다. 아시아태평양, 특히 일본, 중국, 인도 등의 국가에서 희귀질환에 대한 정부의 관심 증가, 의료 접근성 확대, 환자들의 의식 향상 등을 배경으로 아시아태평양이 빠르게 부상하고 있습니다. 그러나 개발도상국에서는 진단시설이 제한적이고 전문적인 치료법도 부족해 해결해야 할 과제가 남아있습니다. 희귀질환 등록을 개선하고 국제 연구 파트너십을 촉진하는 세계 노력으로 지역 간 접근성과 혁신이 지속적으로 강화되어 전 세계 미충족 의료 수요를 충족시키고 있습니다.

희귀질환 치료제 시장 - 경쟁 구도

희귀질환 치료제 시장 경쟁 구도에는 대형 제약사, 생명공학 기업, 희귀질환 전문 스타트업이 혼재되어 있습니다. 젠자임(사노피 산하), 바이오마린, 버텍스 파마슈티컬스 등 업계 선두주자들은 효소대체요법, 유전자치료제 등 혁신적인 치료법을 개발하여 강력한 포트폴리오를 구축하고 있습니다. 중소 바이오텍 기업은 특정 희귀질환을 대상으로 한 틈새 치료제를 제공하고 있으며, 개발 및 상용화를 위해 대기업과 제휴하는 경우가 많습니다. 학계, 환자 지원 단체, 제약사 간의 협력은 일반적으로 연구를 촉진하고 의약품 승인을 가속화하기 위해 이루어지고 있습니다. 희귀질환 치료제 지정 등 규제 우대조치가 희귀질환 치료제에 대한 시장 진입과 투자를 촉진하고 있습니다. 유전자 시퀀싱, 맞춤의료, 바이오의약품의 끊임없는 발전은 혁신을 촉진하고, 희귀질환 환자들의 미충족 수요를 충족시키기 위한 기업간 경쟁이 전 세계에서 치열해지고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석 - 희귀질환 치료 산업

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- Alexion Pharmaceuticals(AstraZeneca)
- Amgen Inc.
- Astellas Pharma Inc.
- BioMarin Pharmaceutical Inc.
- bluebird bio, Inc.
- EveryONE Medicines
- Grifols, SA
- Horizon Therapeutics plc
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- PTC Therapeutics, Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Sanofi SA
- Sarepta Therapeutics, Inc.
- Swedish Orphan Biovitrum AB(Sobi)
- Takeda Pharmaceutical Company Limited
- Ultragenyx Pharmaceutical Inc.
- Vertex Pharmaceuticals Incorporated
- 기타

제14장 애널리스트의 전방위 전망

KSA 25.08.08

REPORT HIGHLIGHT

The Rare Disease Treatment Market size was valued at US$ 216,250.49 Million in 2024, expanding at a CAGR of 11.90% from 2025 to 2032.

The Rare Disease Treatment Market focuses on developing therapies for conditions affecting small patient populations, often with limited existing treatment options. Advances in genetic research and personalized medicine have expanded possibilities, with the World Health Organization noting that over 7,000 rare diseases impact approximately 400 million people worldwide. Increasing government incentives, such as orphan drug designations, encourage pharmaceutical innovation, while challenges include high research costs and complex regulatory pathways. Limited patient awareness and diagnostic delays often hinder early intervention, but growing collaborations between biotech firms, healthcare providers, and patient advocacy groups present opportunities to enhance treatment access and develop novel therapies. Emerging gene therapies and precision medicine approaches are opening new avenues, aiming to improve outcomes for patients with rare and often life-threatening conditions.

Rare Disease Treatment Market- Market Dynamics

Advancements in Genetic Research to Accelerate Rare Disease Treatment Development

Advancements in genetic research have significantly impacted rare disease treatment, enabling targeted therapies and personalized medicine. According to the National Institutes of Health (NIH), nearly 80% of rare diseases are genetic in origin, emphasizing the importance of genomics in diagnosis and treatment. The U.S. Food and Drug Administration (FDA) has granted orphan drug status to numerous gene therapies, facilitating faster approvals and encouraging innovation. Furthermore, global initiatives like the International Rare Diseases Research Consortium (IRDiRC) aim to accelerate the development of diagnostics and treatments, fostering collaboration across countries and disciplines. These efforts, combined with increased patient registries and genetic screening programs, are enhancing early detection and customized care, ultimately improving the quality of life for millions affected by rare diseases worldwide.

Rare Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.90% over the forecast period (2025-2032)

Based on Therapeutic Area segmentation, Hematology was predicted to show maximum market share in the year 2024

Based on Drug Type segmentation, Biologics was the leading Drug Type in 2024

Based on Mode of Administration segmentation, Injectable was the leading Mode of Administration in 2024

Based on Distribution Channel segmentation, Specialty Pharmacies were the leading Distribution Channel in 2024

Based on Patient Age Group segmentation, Adult was the leading Patient Age Group in 2024

On the basis of region, North America was the leading revenue generator in 2024

Rare Disease Treatment Market- Segmentation Analysis:

The Global Rare Disease Treatment Market is segmented on the basis of Therapeutic Area, Drug Type, Mode of Administration, Distribution Channel, Patient Age Group, and Region.

The market is divided into nine categories based on Therapeutic Area: Hematology, Neurology, Oncology, Metabolic Disorders, Immunology, Infectious Diseases, Endocrine Disorders, Cardiovascular Conditions, and Musculoskeletal Conditions. Hematology focuses on blood disorders with targeted therapies. Neurology addresses rare neurological diseases using advanced treatments. Oncology develops specialized cancer therapies. Metabolic disorders rely on enzyme replacement. Immunology targets immune deficiencies, while infectious diseases involve rare infections. Endocrine, cardiovascular, and musculoskeletal conditions have emerging targeted therapies.

The market is divided into two categories based on Drug Type: Biologics and Non-biologics. Biologics dominate rare disease treatment with complex molecules like antibodies and gene therapies, offering targeted action. Non-biologics include small-molecule drugs that provide more traditional treatment options, often used for symptom management and supportive care in various rare conditions.

Rare Disease Treatment Market- Geographical Insights

The Rare Disease Treatment Market exhibits significant geographical variation influenced by healthcare infrastructure, regulatory policies, and awareness levels. North America remains a prominent region due to its advanced healthcare systems, strong government support, and robust funding for rare disease research, supported by agencies like the National Institutes of Health (NIH). Europe follows closely, with comprehensive rare disease networks and initiatives such as the European Reference Networks (ERNs) promoting collaboration among countries for better diagnosis and treatment. The Asia-Pacific region is rapidly emerging, driven by increasing government focus on rare diseases, expanding healthcare access, and growing patient awareness, especially in countries like Japan, China, and India. However, challenges remain in developing regions due to limited diagnostic facilities and a lack of specialized treatments. Global efforts to improve rare disease registries and foster international research partnerships continue to enhance accessibility and innovation across regions, addressing unmet medical needs worldwide.

Rare Disease Treatment Market- Competitive Landscape:

The competitive landscape of the Rare Disease Treatment Market features a blend of large pharmaceutical companies, biotechnology firms, and specialized rare disease-focused startups. Industry leaders like Genzyme (a Sanofi company), BioMarin, and Vertex Pharmaceuticals have established strong portfolios by developing innovative therapies such as enzyme replacement and gene therapies. Smaller biotechs are increasingly contributing niche treatments targeting specific rare conditions, often partnering with larger firms for development and commercialization. Collaborations between academic institutions, patient advocacy groups, and pharmaceutical companies are common, driving research and accelerating drug approvals. Regulatory incentives like orphan drug designations have encouraged market entry and investment in rare disease therapies. Continuous advancements in genetic sequencing, personalized medicine, and biologics are fostering innovation, intensifying competition among players aiming to address the unmet needs of rare disease patients globally.

Recent Developments:

In January 2025, Kerala is set to launch a rare disease patient registry and treatment clinic in Kozhikode this year. The initiative aims to improve early identification and specialized care for rare diseases, expanding access to advanced therapies and enhancing patient survival rates statewide.

In September 2024, India's government is launching a scheme to develop 12 indigenous drugs for eight rare diseases, including muscular dystrophy and Gaucher's disease. This initiative aims to drastically reduce treatment costs and improve access to life-saving therapies for rare disease patients nationwide.

In March 2025, the Mayo Clinic launched a landmark natural history study on autosomal dominant leukodystrophy, a rare neurodegenerative disorder. The initiative aims to improve diagnosis, track disease progression, and lay the groundwork for future genetic therapies and clinical trials in rare neurological diseases.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RARE DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Alexion Pharmaceuticals (AstraZeneca)
Amgen Inc.
Astellas Pharma Inc.
BioMarin Pharmaceutical Inc.
Bluebird bio, Inc.
EveryONE Medicines
Grifols, S.A.
Horizon Therapeutics plc
Ionis Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
PTC Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc.
Roche Holding AG
Sanofi S.A.
Sarepta Therapeutics, Inc.
Swedish Orphan Biovitrum AB (Sobi)
Takeda Pharmaceutical Company Limited
Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated
Others

GLOBAL RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Hematology
Neurology
Oncology
Metabolic Disorders
Immunology
Infectious Diseases
Endocrine Disorders
Cardiovascular Conditions
Musculoskeletal Conditions

GLOBAL RARE DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Biologics
Non-biologics

GLOBAL RARE DISEASE TREATMENT MARKET, BY MODE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Injectable
Oral
Topical

GLOBAL RARE DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies

GLOBAL RARE DISEASE TREATMENT MARKET, BY PATIENT AGE GROUP- MARKET ANALYSIS, 2019 - 2032

Pediatric
Adult
Geriatric

GLOBAL RARE DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Rare Disease Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Rare Disease Treatment Market Snippet by Therapeutic Area
- 2.1.2. Rare Disease Treatment Market Snippet by Drug Type
- 2.1.3. Rare Disease Treatment Market Snippet by Mode of Administration
- 2.1.4. Rare Disease Treatment Market Snippet by Distribution Channel
- 2.1.5. Rare Disease Treatment Market Snippet by Patient Age Group
- 2.1.6. Rare Disease Treatment Market Snippet by Country
- 2.1.7. Rare Disease Treatment Market Snippet by Region
2.2. Competitive Insights

3. Rare Disease Treatment Key Market Trends

3.1. Rare Disease Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Rare Disease Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Rare Disease Treatment Market Opportunities
3.4. Rare Disease Treatment Market Future Trends

4. Rare Disease Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Rare Disease Treatment Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Rare Disease Treatment Market Landscape

6.1. Rare Disease Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Rare Disease Treatment Market - By Therapeutic Area

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
- 7.1.2. Hematology
- 7.1.3. Neurology
- 7.1.4. Oncology
- 7.1.5. Metabolic Disorders
- 7.1.6. Immunology
- 7.1.7. Infectious Diseases
- 7.1.8. Endocrine Disorders
- 7.1.9. Cardiovascular Conditions
- 7.1.10. Musculoskeletal Conditions

8. Rare Disease Treatment Market - By Drug Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
- 8.1.2. Biologics
- 8.1.3. Non-biologics

9. Rare Disease Treatment Market - By Mode of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Mode of Administration, 2024 & 2032 (%)
- 9.1.2. Injectable
- 9.1.3. Oral
- 9.1.4. Topical

10. Rare Disease Treatment Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Specialty Pharmacies
- 10.1.4. Retail Pharmacies

11. Rare Disease Treatment Market - By Patient Age Group

11.1. Overview
- 11.1.1. Segment Share Analysis, By Patient Age Group, 2024 & 2032 (%)
- 11.1.2. Pediatric
- 11.1.3. Adult
- 11.1.4. Geriatric

12. Rare Disease Treatment Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Rare Disease Treatment Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Rare Disease Treatment Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Rare Disease Treatment Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Rare Disease Treatment Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Rare Disease Treatment Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Rare Disease Treatment Industry

13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. Alexion Pharmaceuticals (AstraZeneca)
- 13.2.2. Amgen Inc.
- 13.2.3. Astellas Pharma Inc.
- 13.2.4. BioMarin Pharmaceutical Inc.
- 13.2.5. bluebird bio, Inc.
- 13.2.6. EveryONE Medicines
- 13.2.7. Grifols, S.A.
- 13.2.8. Horizon Therapeutics plc
- 13.2.9. Ionis Pharmaceuticals, Inc.
- 13.2.10. Novartis AG
- 13.2.11. Pfizer Inc.
- 13.2.12. PTC Therapeutics, Inc.
- 13.2.13. Regeneron Pharmaceuticals, Inc.
- 13.2.14. Roche Holding AG
- 13.2.15. Sanofi S.A.
- 13.2.16. Sarepta Therapeutics, Inc.
- 13.2.17. Swedish Orphan Biovitrum AB (Sobi)
- 13.2.18. Takeda Pharmaceutical Company Limited
- 13.2.19. Ultragenyx Pharmaceutical Inc.
- 13.2.20. Vertex Pharmaceuticals Incorporated
- 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us